NovoSeven coagulation factor VIIa (recombinant) for prevention and control of bleeding in patients without hemophilia
Record ID 32011000899
English
Authors' objectives:
NovoSeven® (rFVIIa; Novo Nordisk Inc.) is a commercially produced recombinant human clotting factor VIIa that acts as a local hemostatic agent at the site of ruptured blood vessels to prevent further bleeding and minimize hematoma growth. It is approved for use in patients with hemophilia and other hematologic disorders. Hemostatic effects are localized because tissue factor and activated platelets are only present at the site of blood vessel rupture. NovoSeven is used in nonhemophiliac patients to achieve adequate control of massive bleeding if conventional measures fail. NovoSeven may also be used prophylactically prior to surgical interventions that carry a high risk of excessive bleeding.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=12232
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Blood Coagulation Factor Inhibitors
- Factor VIIa
- Hemophilia A
- Recombinant Proteins
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2011 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.